1. Home
  2. OPFI vs MDWD Comparison

OPFI vs MDWD Comparison

Compare OPFI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OppFi Inc.

OPFI

OppFi Inc.

HOLD

Current Price

$10.73

Market Cap

288.7M

Sector

Finance

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.82

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPFI
MDWD
Founded
2009
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.7M
238.5M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
OPFI
MDWD
Price
$10.73
$18.82
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$13.50
$37.50
AVG Volume (30 Days)
522.8K
93.0K
Earning Date
10-29-2025
11-20-2025
Dividend Yield
2.33%
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$335,423,000.00
$20,932,000.00
Revenue This Year
$120.32
$15.89
Revenue Next Year
$10.85
$25.33
P/E Ratio
$78.29
N/A
Revenue Growth
28.69
6.15
52 Week Low
$6.81
$14.14
52 Week High
$17.73
$22.51

Technical Indicators

Market Signals
Indicator
OPFI
MDWD
Relative Strength Index (RSI) 57.05 55.76
Support Level $10.56 $18.55
Resistance Level $11.18 $19.05
Average True Range (ATR) 0.41 0.57
MACD 0.05 0.06
Stochastic Oscillator 63.80 66.25

Price Performance

Historical Comparison
OPFI
MDWD

About OPFI OppFi Inc.

OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: